UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042083
Receipt number R000048007
Scientific Title Feasibility, safety, and effectiveness of television-based home exercise program (TVEx) on frailty: a pilot prospective randomized open blinded end-point study
Date of disclosure of the study information 2020/10/12
Last modified on 2023/02/28 11:39:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of television-based home exercise program (TVEx) on frailty: a pilot study

Acronym

A pilot study of the TVEx

Scientific Title

Feasibility, safety, and effectiveness of television-based home exercise program (TVEx) on frailty: a pilot prospective randomized open blinded end-point study

Scientific Title:Acronym

A pilot effectiveness study of the TVEx

Region

Japan


Condition

Condition

Frailty

Classification by specialty

Geriatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the feasibility, safety, and effectiveness of the TVEx on frailty.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Change in the score of Short Physical Performance Battery from baseline to post-intervention (after 12 weeks) surveys.

Key secondary outcomes

[Secondary outcome on the effectiveness]
1. Frailty phenotype score
2. Motor function test (gait performance assessed using the GAITRite System, sit and rearch test, up and go test, and knee extension strength)
3. Cognitive function test (verbal memory, logical memory, Symbol Digit Substitution Task, Trail making Test A and B assessed using the National Center for Geriatrics and Gerontology-Functional Assessment Tool)
4. Body composition test (body fat and fat-free mass assessed using the InBody720)
5. Questionnaires (SF-36, home-based exercise self-efficacy, GDS15, LSNS-6, and Kihon Check List)
6. Blood test (Hb, Ht, BG, TP, Alb, LDH, Fe, TC, LDLC, HDLC, TG, and h-CRP)
7. Lifestyle behavior (habitual dietary intake (brief-type self-administered diet history questionnaire), habitual physical activity (active style pro HJA-750C), sleep condition (ActiGraph GT3X+, the Japanese version of the Pittsburgh Sleep Quality Index))

[Safety]
1. Number of all adverse events that occur during the intervention period
2. Blood test (WBC, RBC, AST, ALT, gamma-GTP, PLT, BUN, and Cr)

[Feasibility]
1. When the participation rate in the TVEx is 75% or more and the withdrawal/dropout rate from the intervention is less than 25%, then we consider it as feasible.
2. Total frequency of participating in the TVEx.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Behavior,custom

Interventions/Control_1

Malnutrition prevention + TVEx program
1. Malnutrition prevention program
Participants will receive four documents that introduce detailed methods for preventing malnutrition in their habitual lifestyle and will be asked to record food variety scores every day.
2. TVEx
Participants will be asked to perform three TVExes (radio calisthenics part-1 and -2, calisthenics for everyone), which provided by NIPPON HOSO KYOKAI or DVD, 1-4 times on everyday.

Interventions/Control_2

Malnutrition prevention program
1. Malnutrition prevention program
Participants will receive four documents that introduce detailed methods for preventing malnutrition in their habitual lifestyle and will be asked to record food variety scores every day.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit

100 years-old >

Gender

Male and Female

Key inclusion criteria

1. Community-dwelling older adults aged 65 to 99 years old.
2. Meeting the revised J-CHS frailty or prefrailty crteria.
3. Providing informed consent.

Key exclusion criteria

1. Diagnosed as dementia or prescribed anti-dementia agency.
2. Having a disability in BADL.
3. Exercise restriction ordered by family doctors, except for light-intensity exercise.
4. Having an unstable medical condition or severe diseases, and not approved to participate in the study by the medical doctor.
5. Having experience of angina or myocardial infarction, have heart surgery within the last 3 months, or who are receiving end-stage disease or palliative care.
6. Participating in radio or television calisthenics 1 day/week in the past month.
7. Participating in specific rehabilitation programs.
8. Not able to walk more than 10 m independently.
9. Participate in other clinical trials
10. Not having a TV.
11. Having difficulty in communication by Japanese.
12. Participation of housemates.
13. Judged to be ineligible as a participant by a principal investigator or medical doctor.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Hunkyung
Middle name
Last name Kim

Organization

Tokyo Metropolitan Institute of Gerontology

Division name

Research Team for Promoting Independence and Mental Health

Zip code

173-0015

Address

35-2, Sakae-cho, Itabashi-ku, Tokyo

TEL

03-3964-3241

Email

kimhk@tmig.or.jp


Public contact

Name of contact person

1st name Yosuke
Middle name
Last name Osuka

Organization

Tokyo Metropolitan Institute of Gerontology

Division name

Research Team for Promoting Independence and Mental Health

Zip code

173-0015

Address

35-2, Sakae-cho, Itabashi-ku, Tokyo

TEL

03-3964-3241

Homepage URL


Email

osuka@tmig.or.jp


Sponsor or person

Institute

Tokyo Metropolitan Institute of Gerontology

Institute

Department

Personal name



Funding Source

Organization

The Nakatomi Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology

Address

35-2, Sakae-cho, Itabashi-ku, Tokyo

Tel

03-3964-1141

Email

rinsyoushiken@tmghig.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京都健康長寿医療センター研究所


Other administrative information

Date of disclosure of the study information

2020 Year 10 Month 12 Day


Related information

URL releasing protocol

https://onlinelibrary.wiley.com/doi/10.1111/ggi.14511

Publication of results

Published


Result

URL related to results and publications

https://onlinelibrary.wiley.com/doi/10.1111/ggi.14511

Number of participants that the trial has enrolled

60

Results

Both practice (83%) and retention rates (100%) met the predetermined feasibility criteria. Eleven adverse events were reported but were supposedly unrelated to the intervention. ITT analysis showed that there was no clinically significant difference in the change in SPPB score between groups. On the other hand, the intervention group scored higher in the mental component of HR-QoL than did the control group.

Results date posted

2023 Year 02 Month 28 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

1) community-dwelling older adults aged 65-99 years, 2) meeting pre-frailty or frailty criteria according to the revised Japanese Cardiovascular Health Study, and 3) providing written informed consent.

Participant flow

1. Screening from a trial-ready cohort
2. Recruitment
3. Informed consent
4. Random selection
5. Baseline assessment
6. Random allocation
6. Intervention (12 weeks)
7. Follow-up assessment

Adverse events

Eleven adverse events were reported by intervention participants, and 29 abnormal values in blood parameters were reported. Those seem to be unrelated to the intervention.

Outcome measures

>Primary outcome
Change in the score of Short Physical Performance Battery from baseline to post-intervention (after 12 weeks) surveys.

>Secondary outcomes
1. Frailty phenotype score
2. Motor function test (gait performance assessed using the GAITRite System, sit and rearch test, up and go test, and knee extension strength)
3. Cognitive function test (verbal memory, logical memory, Symbol Digit Substitution Task, Trail Making Test A and B assessed using the National Center for Geriatrics and Gerontology-Functional Assessment Tool)
4. Body composition test (body fat and fat-free mass assessed using the InBody720)
5. Questionnaires (SF-36, home-based exercise self-efficacy, GDS15, LSNS-6, and Kihon Check List)
6. Blood test (Hb, Ht, BG, TP, Alb, LDH, Fe, TC, LDLC, HDLC, TG, and h-CRP)
7. Lifestyle behavior (habitual dietary intake (brief-type self-administered diet history questionnaire), habitual physical activity (active style pro-HJA-750C), sleep condition (ActiGraph GT3X+, the Japanese version of the Pittsburgh Sleep Quality Index))

[Safety]
1. Number of all adverse events that occur during the intervention period
2. Blood test (WBC, RBC, AST, ALT, gamma-GTP, PLT, BUN, and Cr)

[Feasibility]
1. When the participation rate in the TVEx is 75% or more and the withdrawal/dropout rate from the intervention is less than 25%, then we consider it as feasible.
2. Total frequency of participating in the TVEx.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 08 Month 18 Day

Date of IRB

2020 Year 08 Month 18 Day

Anticipated trial start date

2020 Year 10 Month 12 Day

Last follow-up date

2021 Year 08 Month 12 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 10 Month 12 Day

Last modified on

2023 Year 02 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048007


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name